Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
NCT02927080Phase 2Terminated
- Start
- Nov 2016
- Primary completion
- Sep 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of efmitermant alfa in facioscapulohumeral muscular dystrophy (FSHD) (10 arms). Primary endpoints: Incidence of Adverse Events at Day 190, Total Muscle Volume (TMV) of the Treated Muscle at Day 190 and 1 more. Started Nov 2016; status: terminated.
02
Drugs
efmitermant alfa
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT02927080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927080.